OBJECTIVES: To evaluate the BTA stat Test in the detection of recurrent bladder cancer. METHODS: Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer. RESULTS: The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers. CONCLUSIONS: The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer.
OBJECTIVES: To evaluate the BTA stat Test in the detection of recurrent bladder cancer. METHODS: Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer. RESULTS: The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers. CONCLUSIONS: The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer.
Authors: P J Goebell; F Vom Dorp; C Rödel; D Frohneberg; J W Thüroff; D Jocham; C Stief; S Roth; R Knüchel; K W Schmidt; I Kausch; D Zaak; C Wiesner; K Miller; R Sauer; H Rübben Journal: Urologe A Date: 2006-07 Impact factor: 0.639
Authors: C Niedworok; V Rembrink; O W Hakenberg; C Börgermann; R Rossi; T Schneider; M Becker; T Szarvas; C von Ostau; A Swoboda; H Rübben; F vom Dorp Journal: Urologe A Date: 2009-09 Impact factor: 0.639
Authors: A Karl; D Zaak; D Tilki; E Hungerhuber; M Staehler; S Denzinger; P Stanislaus; S Tritschler; F Strittmatter; C Stief; M Burger Journal: Urologe A Date: 2008-03 Impact factor: 0.639